Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.
Neuphoria Therapeutics said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment.
23hon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback